Skip to main content

Lynx s Revenues Fall, Loss Widens in Q4

NEW YORK, April 1 (GenomeWeb News) - Lynx Therapeutics yesterday reported falling revenues and increased losses for the last quarter of 2003.


Revenues for the quarter fell to $2 million, from $4.7 million for the same quarter in 2002. Lynx attributed this decrease primarily to lower fees for its technology and service, and fewer collaborative research projects.


R&D costs decreased to $2.4 million, down from $4.2 million during the year-ago period.


Lynx's net loss amounted to $3.5 million, or $.65 per share, up from $3 million, or $.69 per share, during the fourth quarter of 2002.


As of Dec. 31, Lynx had cash and cash equivalents of $5.6 million, including $0.7 million in restricted cash.


Click here for the full earnings report.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.